This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Sex hormones, which influence sex differences and support puberty and reproduction. These hormones include androgens, estrogens, and progestogens. Corticosteroids, including most synthetic steroid drugs, with natural product classes the glucocorticoids (which regulate many aspects of metabolism and immune function) and the mineralocorticoids (which help maintain blood volume and control renal excretion of electrolytes) Anabolic steroids, natural and synthetic, which interact with androgen receptors to increase muscle and bone synthesis. In popular use, the term "steroids" often refers to anabolic steroids.
Moore opposed Governor Hogan's decision to cancel the Red Line, and said during his 2022 gubernatorial campaign that he supported restarting the rail project. He also called for an "intermodal Red Line, that is built quickly, cost-effectively, and with community input on stops, disruptions, and impact on local businesses". In November 2022, Moore said he would support creating a regional transit authority for working on Baltimore-area transportation projects. In his first budget in January 2023, Moore proposed allocating $500 million toward unspecified transportation projects. When asked by the Capital Gazette if this money would be used for the Red Line, Moore said that he had spoken with federal officials about restarting the line and that he did not want to "start from scratch". He also said he planned to use federal funds and public-private partnerships in transportation projects, including the Purple and Red lines. The budget was amended to reduce this funding to $100 million, but also gave the governor the ability to tap the state's "rainy day" fund for an extra $100 million. On June 15, 2023, Moore announced that he would seek federal funding to restart efforts to build the Red Line. In April 2025, after riding the SCMaglev during a trade trip in Japan, Moore said that he supported a proposed maglev project connecting Washington, D.C. and Baltimore. After the Federal Railroad Administration cancelled grants toward studying a maglev train between Washington, D.C.
== Interaction with other cells == The phenotypes of dermal macrophages can be affected by the cytokines expressed by other immune cells. They can obtain a pro-inflammatory (M1) or anti-inflammatory (M2) phenotype. Cytokines such as IFN-γ skew dermal macrophages to the M1 phenotype, while IL-4 and IL-13 skew them to the M2 phenotype. Phenotype acquisition is the hallmark of macrophage activation. Activation of dermal macrophages can also be achieved by direct contact. Ligands such as CD4 on T cells can trigger dermal macrophages to release pro-inflammatory cytokines during inflammation. This process also preserves the population of circulating monocytes and thereby increases their activity. Dermal macrophages are involved in the adaptive immune system due to their antigen-presenting ability. Dermal macrophages' expression of cell markers like CD11b, F4/80 and MHC II indicate their participation in the MHC II antigen-presenting pathway. However, the MHC II expression is low compared to Langerhans cells, rendering dermal macrophages minor contributors to antigen presentation.
Sources: en.wikipedia.org
=== Oxytocin === Oxytocin (OXT), a hormone most commonly associated with labor and lactation, may have a wide variety of physiological and pathological functions, which makes Oxytocin and its receptor potential targets for drug therapy. OXT may have positive metabolic effects; this is based on the change in glucose metabolism, lipid profile, and insulin sensitivity. It may modify glucose uptake and insulin sensitivity both through direct and indirect effects. It may also cause regenerative changes in diabetic pancreatic islet cells. So, the activation of the OXT receptor pathway by infusion of OXT, OXT analogues, or OXT agonists may represent a promising approach for the management of obesity and related metabolic diseases as well as diabetes and its complications. Oxytocin improves insulin sensitivity by:
== Biography == Yourcenar was born in Brussels, Belgium, as Marguerite Antoinette Jeanne Marie Ghislaine Cleenewerck de Crayencour, to Michel Cleenewerck de Crayencour and Fernande de Cartier de Marchienne. Her father was of French bourgeois descent, originating from French Flanders, and a wealthy landowner. Her mother, of Belgian nobility, died ten days after Marguerite's birth. She grew up in the home of her paternal grandmother, and adopted the surname Yourcenar as a pen name; in 1947, she also took it as her legal surname. Yourcenar's first novel, Alexis, was published in 1929. She translated Virginia Woolf's The Waves over a ten-month period in 1937. In 1939, her partner at the time, the literary scholar and Kansas City native Grace Frick, invited Yourcenar to the United States to escape the outbreak of World War II in Europe. She lectured in comparative literature in New York City and Sarah Lawrence College. Yourcenar and Frick became lovers in 1937 and remained together until Frick's death in 1979. After ten years spent in Hartford, Connecticut, they bought a house in Northeast Harbor, Maine, on Mount Desert Island, where they lived for decades. They are buried next to each other at Brookside Cemetery, Somesville, Mount Desert, Maine. Yourcenar's last companion was Jerry Wilson, with whom she had a tormented relationship; he died of AIDS in 1986. In 1951, Yourcenar published, in France, the novel Memoirs of Hadrian, which she had been writing on and off for a decade. The novel was an immediate success and met with critical acclaim.
=== Acidity/basicity === Ionic compounds containing hydrogen ions (H+) are classified as acids, and those containing electropositive cations and basic anions ions hydroxide (OH−) or oxide (O2−) are classified as bases. Other ionic compounds are known as salts and can be formed by acid–base reactions. Salts that produce hydroxide ions when dissolved in water are called alkali salts, and salts that produce hydrogen ions when dissolved in water are called acid salts, e.g. sodium hydrogen selenite (NaHSeO3). If the compound is the result of a reaction between a strong acid and a weak base, the result is an acid salt. If it is the result of a reaction between a strong base and a weak acid, the result is a base salt. If it is the result of a reaction between a strong acid and a strong base, the result is a neutral salt. Weak acids reacted with weak bases can produce ionic compounds with both the conjugate base ion and conjugate acid ion, such as ammonium acetate. Some ions are classed as amphoteric, being able to react with either an acid or a base. This is also true of some compounds with ionic character, typically oxides or hydroxides of less-electropositive metals (so the compound also has significant covalent character), such as zinc oxide, aluminium hydroxide, aluminium oxide and lead(II) oxide.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.